0
0

340B ACCESS Act

12/19/2024, 9:06 AM

Summary of Bill HR 8574

The Bill 118 hr 8574, also known as the 340B ACCESS Act, aims to address issues related to the 340B Drug Pricing Program. This program requires drug manufacturers to provide discounts on outpatient drugs to certain healthcare facilities that serve low-income and vulnerable populations.

The 340B ACCESS Act seeks to improve transparency and accountability within the program by requiring participating healthcare facilities to report on how they are using the discounts they receive. This information will be made publicly available in order to ensure that the discounts are being used to benefit the intended populations.

Additionally, the bill includes provisions to address concerns about the increasing costs of prescription drugs. It requires drug manufacturers to provide additional discounts on drugs that have seen significant price increases, in order to help mitigate the financial burden on patients and healthcare facilities. Overall, the 340B ACCESS Act aims to strengthen the 340B Drug Pricing Program and ensure that it is effectively serving its intended purpose of providing affordable medications to low-income and vulnerable populations.

Current Status of Bill HR 8574

Bill HR 8574 is currently in the status of Bill Introduced since May 28, 2024. Bill HR 8574 was introduced during Congress 118 and was introduced to the House on May 28, 2024.  Bill HR 8574's most recent activity was Referred to the Subcommittee on Health. as of December 17, 2024

Bipartisan Support of Bill HR 8574

Total Number of Sponsors
2
Democrat Sponsors
0
Republican Sponsors
2
Unaffiliated Sponsors
0
Total Number of Cosponsors
2
Democrat Cosponsors
0
Republican Cosponsors
2
Unaffiliated Cosponsors
0

Policy Area and Potential Impact of Bill HR 8574

Primary Policy Focus

Health

Alternate Title(s) of Bill HR 8574

To amend the Public Health Service Act to reform the 340B drug pricing program, and for other purposes.
To amend the Public Health Service Act to reform the 340B drug pricing program, and for other purposes.

Comments